SANTA CLARA, Calif. / Jul 31, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) today released its 2022 ESG report on the company’s work supporting customers with their sustainability initiatives while advancing its own internal high-priority ESG programs, from reducing Scope 3 emissions in the value chain to cultivating a talented, diverse, and inclusive workforce.
“Agilent is committed to our customers’ success at every stage of their journey to bring great science to life,” said Agilent President and CEO Mike McMullen. “That includes helping them achieve their sustainability goals with our products, technology, and services. At the same time, we’re driving ESG objectives within our operations by fostering a great workplace, and investing in a diverse pipeline of talent, which is essential to our company’s future.”
The report also covers the role of Agilent products and technology in addressing some of society’s biggest challenges—from improving outcomes for cancer patients to helping measure exposure to substances such as PFAS.
Below are some of the highlights from fiscal 2022 in four focus areas of Agilent’s ESG program:
People
Planet
Products
Prosperity
Agilent’s 2022 report also includes an updated Task Force on Climate-Related Financial Disclosures (TCFD) report, an index of materially relevant topics from the Global Reporting Initiative (GRI), and a SASB index. Read the report and related materials about Agilent’s ESG program at Agilent.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Last Trade: | US$121.03 |
Daily Change: | -15.07 -11.07 |
Daily Volume: | 1,901,213 |
Market Cap: | US$34.570B |
December 10, 2024 November 14, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load